CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight
The CAR T-cell therapy for NHL market is witnessing rapid expansion, driven by the transition from conventional chemo-immunotherapy to advanced cell-based treatment modalities. Strong efficacy in R/R disease, growing adoption in 2L and beyond, and the launch of emerging therapies such as...
The CAR T-cell therapy for NHL market is witnessing rapid expansion, driven by the transition from conventional chemo-immunotherapy to advanced cell-based treatment modalities. Strong efficacy in R/R disease, growing adoption in 2L and beyond, and the launch of emerging therapies such as...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.